AOD-9604 and semaglutide are very different compounds. Semaglutide is a GLP-1 receptor agonist with FDA-approved products for type 2 diabetes and chronic weight management. AOD-9604 is a modified fragment of human growth hormone that has been studied for metabolic effects but is not an FDA-approved weight-loss medication.
Semaglutide activates GLP-1 receptors involved in appetite, satiety, glucose regulation and gastric emptying. Its weight-management effects are supported by large randomized clinical trials.
AOD-9604 is a synthetic peptide fragment derived from part of the human growth hormone molecule. It has been investigated for effects on fat metabolism, but available evidence does not place it in the same category as FDA-approved anti-obesity medications.
Semaglutide has substantially stronger clinical evidence for obesity treatment. AOD-9604 should not be presented as equivalent to semaglutide or other FDA-approved weight-management medications.
Patients should distinguish FDA-approved medications from experimental or compounded peptide products. Product quality, dosing, evidence and regulatory status differ significantly.
The best medication depends on BMI, medical history, diabetes status, prior treatment, side effects, contraindications and treatment goals.
Learn more about semaglutide in Los Angeles, weight-loss medications, and peptide therapy for weight loss.
